Radiopharmaceuticals

Excel Diagnostics and Nuclear Oncology Center Announces FDA Authorization of IND for 225Ac-PSMA I&T Targeted Alpha Therapy for Castration Resistant Prostate Cancer

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Health sciences, Chemistry, Radiopharmaceuticals, Orphan drugs, Chelating agents, Macrocycles, Glutamate carboxypeptidase II, Proteases, MCRPC, DOTA-TATE, Prostate cancer

Houston, TX, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Excel Diagnostics and Nuclear Oncology Center (EDNOC), a premier Diagnostic Imaging and Radioligand Therapy center in Houston, Texas announces approval of its physicians sponsored Investigational New Drug (IND) application for providing Targeted Alpha Therapy (TAT) with 225Ac-PSMA I&T for metastatic Castration-Resistant Prostate Cancer (mCRPC).

Key Points: 
  • Houston, TX, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Excel Diagnostics and Nuclear Oncology Center (EDNOC), a premier Diagnostic Imaging and Radioligand Therapy center in Houston, Texas announces approval of its physicians sponsored Investigational New Drug (IND) application for providing Targeted Alpha Therapy (TAT) with 225Ac-PSMA I&T for metastatic Castration-Resistant Prostate Cancer (mCRPC).
  • Excel Diagnostics and Nuclear Oncology Center has been a pioneer in bringing new targeted Radioligand Therapies such as Lu-177 DOTATATE, and Lu-177 PSMA to serve our patients in the United States.
  • Highly encouraging results have been reported by using Targeted Alpha Therapy (TAT) Radiopharmaceuticals in conditions such as neuroendocrine, prostate, or hematological malignancies.
  • In April of 2020, Excel passed FDA inspection of one of its investigational drugs with no deficiencies or citations.

NorthStar Medical Radioisotopes and GE Healthcare Sign Exclusive U.S. Manufacturing and Distribution Agreement

Retrieved on: 
Tuesday, August 3, 2021
Medical Supplies, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, Medicine, Health sciences, Radiopharmaceuticals, Physical sciences, Medical physics, Medicinal radiochemistry, Medicinal chemistry, Nuclear medicine, GE Healthcare, General Electric, Medical imaging, Radiopharmacology

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, and GE Healthcare today announced the signing of an exclusive agreement for the manufacturing and distribution of iodine-123 (I-123) capsules in the United States.

Key Points: 
  • NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, and GE Healthcare today announced the signing of an exclusive agreement for the manufacturing and distribution of iodine-123 (I-123) capsules in the United States.
  • This exclusive sales and manufacturing agreement marks NorthStars strong and growing relationship with GE Healthcare, and we look forward to working with the company in meeting the needs of radiopharmacy customers and the patients we all serve, said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes.
  • GE Healthcare Pharmaceutical Diagnostics imaging agents support three patient procedures every second worldwide across MRI, X-ray/CT, ultrasound and nuclear medicine imaging.
  • GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE).

Council on Radionuclides and Radiopharmaceuticals, Inc. Supports the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021

Retrieved on: 
Tuesday, July 27, 2021
Surgery, Medical devices, Public policy, Government, Healthcare reform, Biotechnology, Other Health, Radiology, Health, Oncology, Physical sciences, Natural sciences, Medicinal radiochemistry, Chemistry, Isotopes, Radiopharmaceuticals, Medicinal chemistry, Nuclear medicine, Radiology, Medicare, Radionuclide, Medicine

The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R.

Key Points: 
  • The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R.
  • 4479, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 by Congressmen Scott Peters (D-CA), Bobby Rush (D-IL), Neal Dunn (R-FL) and Greg Murphy (R-NC).
  • The FIND Act will ensure that patients have access to precision diagnostic radiopharmaceutical (RP) drugs and promotes continued life-saving innovations in nuclear medicine.
  • The current Medicare reimbursement structure in the outpatient setting packages diagnostic RP drugs into nuclear medicine procedure payments.

Farid Fezoua joins TVM Capital Healthcare as Managing Partner

Retrieved on: 
Monday, July 5, 2021
Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Health care

DUBAI, UAE, SINGAPORE, BOSTONand MUNICH, July 5, 2021 /PRNewswire/ -- TVM Capital Healthcare, a global specialist healthcare private equity firm operating in emerging markets, announced today that Farid Fezoua joins the firm as a Managing Partner.

Key Points: 
  • DUBAI, UAE, SINGAPORE, BOSTONand MUNICH, July 5, 2021 /PRNewswire/ -- TVM Capital Healthcare, a global specialist healthcare private equity firm operating in emerging markets, announced today that Farid Fezoua joins the firm as a Managing Partner.
  • Farid comes to TVM Capital Healthcare following the successful exit of Cambridge Medical and Rehabilitation Center (CMRC) in March 2021 for $232 million, which represented a 4.6x return on capital invested the largest MENA healthcare deal in recent years.
  • Farid Fezoua, Managing Partner, TVM Capital Healthcare, said: "There are countless opportunities for healthcare investments in both the MENA and Southeast Asia regions, so it is an exciting time to be joining a dedicated healthcare private equity investor.
  • Mr. Fezoua will also become Chairman of the Board at TVM Capital Healthcare's portfolio company, Manzil Healthcare Services, replacing the firm's Operating Partner, Carl Stanifer, who will focus on TVM Capital Healthcare's investment and company building plans in Southeast Asia.

Farid Fezoua joins TVM Capital Healthcare as Managing Partner

Retrieved on: 
Monday, July 5, 2021
Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Health care

DUBAI, UAE, SINGAPORE, BOSTONand MUNICH, July 5, 2021 /PRNewswire/ -- TVM Capital Healthcare, a global specialist healthcare private equity firm operating in emerging markets, announced today that Farid Fezoua joins the firm as a Managing Partner.

Key Points: 
  • DUBAI, UAE, SINGAPORE, BOSTONand MUNICH, July 5, 2021 /PRNewswire/ -- TVM Capital Healthcare, a global specialist healthcare private equity firm operating in emerging markets, announced today that Farid Fezoua joins the firm as a Managing Partner.
  • Farid comes to TVM Capital Healthcare following the successful exit of Cambridge Medical and Rehabilitation Center (CMRC) in March 2021 for $232 million, which represented a 4.6x return on capital invested the largest MENA healthcare deal in recent years.
  • Farid Fezoua, Managing Partner, TVM Capital Healthcare, said: "There are countless opportunities for healthcare investments in both the MENA and Southeast Asia regions, so it is an exciting time to be joining a dedicated healthcare private equity investor.
  • Mr. Fezoua will also become Chairman of the Board at TVM Capital Healthcare's portfolio company, Manzil Healthcare Services, replacing the firm's Operating Partner, Carl Stanifer, who will focus on TVM Capital Healthcare's investment and company building plans in Southeast Asia.

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

Retrieved on: 
Tuesday, June 15, 2021
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Health sciences, Medicine, Natural sciences, Radiopharmaceuticals, Medicinal radiochemistry, Medicinal chemistry, Rockefeller family, Venrock, TCG

RayzeBio, Inc., which is discovering and developing a broad pipeline of innovative targeted radiopharmaceutical drugs for cancer, today announced a $108 million Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.

Key Points: 
  • RayzeBio, Inc., which is discovering and developing a broad pipeline of innovative targeted radiopharmaceutical drugs for cancer, today announced a $108 million Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
  • The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated, said Ken Song, M.D., president and CEO of RayzeBio.
  • With over $258 million of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.
  • RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes.

Y-mAbs Announces Update on Omburtamab for DIPG

Retrieved on: 
Friday, June 4, 2021
Chemical elements, Pediatric cancers, Chemistry, Physical sciences, Brain tumor, Chlorides, Radiopharmaceuticals, Medulloblastoma, Lutetium, Neuroblastoma, Blastoma

We are excited to share these results that significantly broaden the potential reach of omburtamab, which would be addressing a clear unmet medical need.

Key Points: 
  • We are excited to share these results that significantly broaden the potential reach of omburtamab, which would be addressing a clear unmet medical need.
  • The results pave the way for our multicenter phase 2 study in DIPG later this year, where we expect to give up to three repeated doses of omburtamab, stated Thomas Gad, founder, Chairman and President.
  • Dr. Claus Moller, Chief Executive Officer, continued, We are expanding our omburtamab franchise significantly this year.
  • While the iodine labeled omburtamab targets DIPG, CNS/LM from neuroblastoma and DSRCT, we have also initiated clinical trials for medulloblastoma and B7-H3 positive CNS metastasis with our lutetium labeled omburtamab.

GE Healthcare and the American College of Cardiology Join Forces to Advance AI in Cardiac Care

Retrieved on: 
Thursday, June 3, 2021
Hardware, Technology, Continuing, University, Radiology, Pharmaceutical, Education, Training, Medical devices, Other Technology, Cardiology, Science, Biotechnology, Health, Research, Companies, Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Economy of the United States, Industry economics), General Electric, John S. Rumsfeld, GE Technology Infrastructure

GE Healthcare will lend its unique perspective as a leading global medical technology and digital solutions innovator in connected cardiovascular care to this forum.

Key Points: 
  • GE Healthcare will lend its unique perspective as a leading global medical technology and digital solutions innovator in connected cardiovascular care to this forum.
  • We are excited to have GE Healthcare join forces with the Applied Health Innovation Consortium, says John Rumsfeld, MD, PhD, FACC, ACC Chief Innovation Officer and Chief Science & Quality Officer.
  • In our mission to transform cardiovascular care and improve heart health, GE Healthcare is a great collaborator to help build a roadmap for AI and digital technology that bridges gaps in clinical care.
  • GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE).

Curium Acquires Austrian Radiopharmaceuticals Company IASON

Retrieved on: 
Tuesday, June 1, 2021
Physical sciences, Chemistry, Natural sciences, Medicinal radiochemistry, Radiopharmaceuticals, Medical imaging, Radiology, Curium, Marie Curie, Positron Corporation, Nuclear medicine, Iason

Paris, May 31, 2021 (GLOBE NEWSWIRE) -- (Graz and Paris June 1st, 2021) Curium has successfully completed the acquisition of the Austrian radiopharmaceuticals Company IASON, further expanding its footprint in Europe for its broad portfolio of life saving diagnostic solutions.

Key Points: 
  • Paris, May 31, 2021 (GLOBE NEWSWIRE) -- (Graz and Paris June 1st, 2021) Curium has successfully completed the acquisition of the Austrian radiopharmaceuticals Company IASON, further expanding its footprint in Europe for its broad portfolio of life saving diagnostic solutions.
  • We are looking forward to integrating IASON into our network of 27 PET sites across Europe says Benoit Woessmer, CEO of PET EUROPE at Curium.
  • The name Curium honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine.
  • IASON, founded in 1994, is an independent Austrian company IASON is a leading specialist in Europe for the development, production and distribution of radiopharmaceuticals for positron-emission-tomography (PET).

Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery

Retrieved on: 
Monday, May 24, 2021
Physical sciences, Chemistry, Chemical elements, Radiopharmaceuticals, Medicinal radiochemistry, Medicinal chemistry, Chlorides, Radiation therapy, Radiopharmacology, Actinium(III) iodide, Actinium(III) chloride, Provisional application

WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled Bio-Targeted Radiopharmaceutical Compositions Containing Ac-225 and Methods of Preparation.

Key Points: 
  • WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled Bio-Targeted Radiopharmaceutical Compositions Containing Ac-225 and Methods of Preparation.
  • Radiopharmaceutical therapy is a promising approach to treat cancer and other diseases using radioactive metals bound with proteins/antibodies to target and kill cells.
  • If validated through further evaluation, it could potentially improve efficacy and safety and enhance manufacturing efficiency of Actinium-based radiopharmaceuticals.
  • Monopar and NorthStar plan to explore both internal development and out-licensing opportunities of this promising approach in Actinium-based radiopharmaceuticals.